CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
将双打击淋巴瘤纳入侵袭性淋巴瘤谱：方枘圆凿？
英文原题：Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
查看英文原题
Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
伴MYC和BCL2和/或BCL6重排的高级别B细胞淋巴瘤，通常称为双打击淋巴瘤（DHL），是一种侵袭性B细胞淋巴瘤，在分子上有别于弥漫性大B细胞淋巴瘤（DLBCL），且预后较差。近期DLBCL分子分型进展识别出多个不同亚群，包括与DHL及生存相关的遗传学特征。伴TP53突变的DHL似乎预后尤其不良。标准化疗免疫治疗对此类患者疗效欠佳，需要个体化创新策略。本文综述DLBCL亚型分类的近期进展，重点关注DHL，并纳入采用CAR-T 细胞和靶向治疗的早期、前景良好的临床试验数据。需要设计合理的DLBCL临床试验，以改善DHL及其他不良风险DLBCL亚组患者的治疗。
展开英文摘要原文
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements or both, commonly called double-hit lymphoma (DHL), is an aggressive B-cell lymphoma that is molecularly distinct from diffuse large B-cell lymphoma (DLBCL) and is associated with poor outcomes. Recent advances in the molecular classification of DLBCL have identified distinct subsets, including genetic signatures which correlate with DHL and survival.
DHL with concomitant TP53 mutation appears to be associated with a very poor prognosis. Standard chemo-immunotherapy is not an effective treatment for these patients and personalized, innovative strategies are needed. In this review, we summarize recent advances in the subclassification of DLBCL, with a focus on DHL.
We also incorporate early, promising clinical trial data using CAR T and targeted therapies. Rationally designed clinical trials for DLBCL are needed to advance the care of patients with DHL and other adverse risk DLBCL subgroups.
论文信息
- 作者
- Gordon MJ、Westin JR
- 单位
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA.United States
- 文献类型
- 综述
- 期刊
- Leukemia & lymphoma2022 May
- 原文标识
- PubMed 34842019 · DOI 10.1080/10428194.2021.2008383